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Nutrition therapy, first introduced 6 decades ago, remains the 
primary treatment for phenylalanine hydroxylase (PAH) defi-
ciency.1–3 The goals of lifelong nutrition therapy include normal 
physical growth and neurocognitive development, maintenance 
of adult health, and normal gestational outcomes in pregnant 
women with PAH deficiency. Knowledge of metabolism, the 
pathophysiology of PAH deficiency, and the role of nutrition 
has led to new and improved treatment options, modified low-
protein foods, and medical foods that provide protein equiva-
lents and other nutrients when intact protein food sources must 
be limited. Table 1 contains definitions of modalities used in 
the nutrition treatment of aminoacidopathies, including PAH 
deficiency. Lifelong treatment is recommended because of the 
negative association between elevated blood phenylalanine 
(PHE) and neurocognition, yet national nutrition recommen-
dations for PAH deficiency are lacking. The goals of the present 
evidence- and consensus-based recommendations are to trans-
late current knowledge to patient care, foster more harmoni-
ous clinical practices, and promote healthy eating, with the 
ultimate goal of ensuring better outcomes for individuals with 
PAH deficiency. This document serves as a companion to the 
concurrently published American College of Medical Genetics 
and Genomics (ACMG) guideline for the medical treatment of 
PAH deficiency.4
MATERIALS AND METHODS
Recommendations were developed by a cooperative effort 
among Genetic Metabolic Dietitians International, the Southeast 
Regional Genetics Collaborative, and dietitians from the Diet 
Control and Management and Maternal PKU Workgroups from 
the National Institutes of Health Phenylketonuria Scientific 
Review Conference2 held in February 2012. The evidence for 
these recommendations represents the synthesis of information 
from the National Institutes of Health 2000 (ref. 2) and Agency 
for Healthcare Research and Quality 2012 (ref. 1) reviews and the 
literature review completed by the National Institutes of Health 
Phenylketonuria Scientific Review Conference workgroups. 
PubMed was the primary database for the National Institutes of 
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The effectiveness of a phenylalanine-restricted diet to improve the 
outcome of individuals with phenylalanine hydroxylase deficiency 
(OMIM no. 261600) has been recognized since the first patients 
were treated 60 years ago. However, the treatment regime is complex, 
costly, and often difficult to maintain for the long term. Improve-
ments and refinements in the diet for phenylalanine hydroxylase 
deficiency have been made over the years, and adjunctive therapies 
have proven to be successful for certain patients. Yet evidence-based 
guidelines for managing phenylalanine hydroxylase deficiency, opti-
mizing outcomes, and addressing all available therapies are lacking. 
Thus, recommendations for nutrition management were developed 
using evidence from peer-reviewed publications, gray literature, and 
consensus surveys. The areas investigated included choice of appro-
priate medical foods, integration of adjunctive therapies, treatment 
during pregnancy, monitoring of nutritional and clinical markers, 
prevention of nutrient deficiencies, providing of access to care, and 
compliance strategies. This process has not only provided assessment 
and refinement of current nutrition management and monitoring 
recommendations but also charted a direction for future studies. 
This document serves as a companion to the concurrently published 
American College of Medical Genetics and Genomics guideline for 
the medical treatment of phenylalanine hydroxylase deficiency.
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Health Phenylketonuria Scientific Review Conference scientific 
literature searches. Search terms were specific to each question 
(as described in the ACMG guideline4), but inclusion and exclu-
sion criteria were the same for all questions.
Consensus-based tools used to support these recommenda-
tions were the National Institutes of Health expert panel sum-
mary (described in the companion paper), a PAH Deficiency 
Delphi survey,5 and an Inborn Errors of Metabolism (IEM) 
survey (D.M. Frazier, S.C. van Calcar, et al., personal commu-
nication). The Delphi process is a component of the guideline 
development model that uses accepted methods for evidence 
analysis, with the addition of consensus techniques to address 
clinical practice issues for which research is lacking.6 The 
Delphi survey, an online survey in which participants indi-
cated their level of agreement or disagreement with practice 
statements, was answered by 17 experts from the seven Health 
Resources and Services Administration Regional Genetics and 
Newborn Screening Collaboratives. When the level of agree-
ment was 80% or greater, the information was added to the evi-
dence summaries in these recommendations. The IEM survey, 
also online, was conducted following the National Institutes 
of Health–sponsored Nutrition and Dietary Supplement 
Interventions for Inborn Errors of Metabolism Workshop 
that was held in December 2011. Information about the use of 
nutritional treatments and supplements by metabolic special-
ists managing individuals with PAH deficiency was collected 
from 82 survey respondents.
BLOOD PHE AND TYROSINE (TYR) cONTROL
Target blood PHE
Blood PHE has been used to monitor metabolic status and 
determine appropriate dietary PHE intake and has been shown 
to be a reliable predictor of clinical outcomes.7 The companion 
ACMG PAH deficiency treatment guideline supports a life-
long target blood PHE of 120–360 µmol/l for optimal cogni-
tive outcome.4 Eighty percent of Delphi respondents supported 
120–360 µmol/l as a goal blood PHE for individuals with PAH 
deficiency of all ages, yet there was recognition that the goal 
is difficult to achieve and may not apply in all cases.5 Regular 
blood PHE monitoring is key to the management of PAH 
deficiency. During infancy, early childhood, and pregnancy, 
more frequent monitoring is necessary to assess the increased 
dietary PHE needs of anabolism3 (Table 2). The British Medical 
Research Council guidelines recommend measuring PHE 
concentrations at a standard time3; there was a consensus that 
blood samples be collected at the same time of day, preferably 
2–3 hours after a meal.5 It is recommended that medical food 
be consumed throughout the day to maintain stable concentra-
tions of blood PHE.8
Target blood TYR and PHE:TYR ratio
Because both endogenous production of TYR and intact pro-
tein intake are greatly limited in PAH deficiency, monitoring 
is necessary to ensure that supplementation is adequate to 
maintain the blood TYR in the normal range. Some clinicians 
routinely monitor blood PHE:TYR ratios.9 There are reports 
of impairments in executive function among individuals with 
high PHE:TYR ratios.9,10 However, at this time the clinical rel-
evance of PHE:TYR as a routine biomarker requires further 
study.
THE INFLUENcE OF GENOTYPE ON NUTRITION 
TREATMENT
As described in the ACMG guideline,4 individuals with PAH 
deficiency have been categorized by phenotype (PHE tolerance 
and blood PHE concentrations) and genotype.4 PHE tolerance 
is defined as the amount of dietary PHE (mg/day) an individ-
ual with PAH deficiency can consume while maintaining blood 
PHE in the treatment range.11 Although individuals with PAH 
deficiency are represented by a spectrum of residual enzyme 
activity, some practitioners find practical utility in referring to 
the older categories: “classic/severe,” “moderate,” “mild,” and 
“mild hyperphenylalaninemia not needing PHE restriction.”
Treatment by phenotype and PHE tolerance
In clinical practice, PHE tolerance can often be determined 
by 2–5 years of age.12 However, because PHE tolerance can 
change during periods of rapid growth or changes in lifestyle, 
Table 1 Definitions of modalities used for treatment of aminoacidopathies
Medical food: A food that is formulated to be consumed or administered enterally under the supervision of a physician and that is intended for the 
specific dietary management of a disease or condition for which distinctive nutritional requirements, based on recognized scientific principles, are 
established by medical evaluation (section 5(b), Orphan Drug Act (21 USC 360ee (b)(3)61)).
Modified low-protein food: Food products specially formulated to contain less than 1 g of protein per serving. Low-protein modified food products are 
intended for use under the direction of a physician for the dietary treatment of hereditary metabolic diseases. Examples of commercially available low-
protein food products include breads, pasta, baking mix, and imitation cheese.
Intact protein: Food-derived, natural protein.
Protein equivalent: Containing an equivalent amount of nitrogen as found in a complete protein. For medical foods, this is often used to describe the free 
amino acids that replace intact protein.
REcOMMENDATIONS
•	 Maintain blood PHE between 120 and 360 μmol/l 
throughout the life span for optimal outcome.
•	 Monitor blood PHE most frequently during times of in-
creased anabolism: infancy, childhood, and pregnancy.
•	 Monitor blood PHE at a consistent time during the day, 
preferably 2–3 hours after eating.
•	 Maintain blood TYR in the normal range.
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Table 2 Monitoring the nutritional management of individuals with PAH deficiencya
Outcomes Infants children Adults
Pregnancy and postpartum 
period
Domain measures (0–1 year) (1–7 years) (8–18 years) Adults Pregnancy Postpartum 
lactation
Clinical assessment
   Nutrition visit in clinic (dietary intakeb 
and nutrient analysis, nutrition-
















   Anthropometricsc (weight, length or 





At every clinic 












   Interval nutrition visit (diet 
adjustment based on blood PHE and/




Weekly to monthly Weekly to 
monthly




  Psychological As outlined in the 
ACMG guideline 
Table 2 (ref. 4)
  Biochemical (routine)




Weekly to monthly Weekly to 
monthly








Weekly to monthly Weekly to 
monthly




    Amino acids, plasma Monthly to 
every 3 months
At every clinic visit At every 
clinic visit






    Transthyretin (prealbumin) 6–12 months 6–12 months 6–12 months 6–12 months Monthly to 
per trimester
Yearly
    Albumin/total protein 6–12 months 6–12 months 6–12 months 6–12 months Per trimester Yearly
    Complete blood count Yearly Yearly Yearly Yearly Per trimester Yearly
    Ferritin Yearly Yearly Yearly Yearly Per trimester Yearly
    Vitamin D 25-OH Yearly Yearly Yearly Yearly Per trimester Yearly
  Biochemical (conditional)
     Comprehensive metabolic panel, 
serum vitamin B12, B6, erythrocyte 
folate, vitamin A, zinc, copper, 
selenium, essential fatty acids








    DXA NA NA Every 3–5  
years begin n -
ing at age 8f
Every 5 years NA NA
ACMG, American College of Medical Genetics and Genomics; BMI, body mass index; DXA, dual-energy X-ray absorptiometry; NA, not applicable; PAH, phenylalanine 
hydroxylase; PHE, phenylalanine; TYR, tyrosine.
aRecommendations were derived from Delphi and Nominal group consensus on monitoring of aminoacidopathies and the Newborn Screening Translational Research 
Network. Frequency of clinical and laboratory assessments at a metabolic clinic (involving the medical geneticist, metabolic dietitian, social worker, nurse specialist, 
psychologist, and others) may not be possible for reasons such as travel distance, cost, and loss of work days. Coordination with primary-care and community-based 
providers, use of telemedicine, and frequent communication by telephone and mail should be employed. More frequent monitoring may be necessary if the individual is 
not in good metabolic control.
bA mechanism for assessing dietary intake, whenever PHE is monitored, should be in place. MetabolicPro (http://www.metabolicpro.org) is a computer program available 
for dietary analysis of amino acid–restricted diets.
cThe Centers for Disease Control and Prevention (CDC) recommends using the 2006 World Health Organization (WHO) Child Growth Standards to evaluate growth of 
infants from birth to age 24 months. The CDC recommends using the 2000 CDC Growth Charts to evaluate the growth of children from age 2 to 20 years. Techniques for 
measurement are described on the CDC website (http://www.cdc.gov/growthcharts/cdc_charts.htm).
dMonitoring protocols may include mail-in blood specimens (using filter paper cards or capillary tubes) or use of local laboratories or the State Laboratory of Public Health. 
Such protocols are optimal for increasing the frequency of monitoring. When plasma amino acid analysis is the only available means of PHE and TYR monitoring, access 
and cost may force less-frequent monitoring.
eMonitoring is indicated when nutrition assessment indicates poor adherence to diet or inadequate medical food consumption, or when there has been consumption of 
an incomplete medical food, clinical signs/symptoms of nutritional inadequacy including poor growth, or serious intercurrent illness. If laboratory values are abnormal, 
reassessment of specific analytes should be scheduled within 1 month of intervention.
fDXA is indicated in individuals who have frequent fractures and/or low serum 25-hydroxy vitamin D concentrations.
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it is important to reassess PHE tolerance periodically by assess-
ing dietary PHE intake with blood PHE.11,13 Predicting PHE 
tolerance may be useful when communicating expectations to 
families, assessing responsiveness to adjunctive therapy,14 and 
planning dietary prescriptions.
Those with little residual PAH activity (“classic PKU”) will 
require the most medical food as their primary source of 
protein equivalents.15 Modified low-protein foods should be 
introduced early to meet critical energy needs and maintain 
metabolic control in this group. For individuals with mild or 
moderate PAH deficiency, less medical food and/or modified 
low-protein food is needed to maintain blood PHE control.16 
Such individuals are also more likely to respond to sapropterin, 
which has the potential for allowing liberalization of the diet. 
The need to treat individuals with very mild hyperphenylal-
aninemia remains under debate.17
Even with classification by genotype or phenotype, addi-
tional factors can affect the management of PAH deficiency. 
Individualized treatment plans must reflect the patient’s unique 
genetic makeup, general health, intercurrent illness, growth 
requirements, activity level, pregnancy/lactation status, and 
access to care.
NUTRIENT REQUIREMENTS, SOURcES, AND 
MONITORING
Nutrient requirements for individuals with PAH deficiency do 
not differ from those of the general population, except for PHE, 
TYR, and protein (Table 3).3,18–20 Concern about the nutritional 
adequacy of the diet arises because the severe restriction of 
foods containing intact protein necessitates lifelong reliance on 
semisynthetic medical foods, from which some nutrients may 
not be as well absorbed. In addition, nonadherence to medical 
food consumption, or reliance on nutritionally incomplete medi-
cal foods, increases the risk of multiple nutrient deficiencies. 
Therefore, monitoring of nutrient intake and laboratory indexes 
of nutritional adequacy is recommended (Table 2).
Protein and amino acids
Because medical food is the primary source of protein equiva-
lents in the diet for PAH deficiency, it is a critical component 
of the diet throughout life. Recommendations for total pro-
tein intake exceed age- and sex-specific Dietary Reference 
Intakes because l-amino acids found in most medical foods 
are absorbed and oxidized more rapidly than amino acids in 
intact protein.21,22 Traditionally, l-amino acids (without PHE) 
have been the source of protein equivalents in medical foods, 
but more recently, glycomacropeptide (GMP), an intact protein 
that is low in PHE, has been used as a protein source in com-
bination with limiting l-amino acids.23 l-Amino acid–based or 
GMP-based medical foods provide ~85% of the protein needs 
of individuals with a severe form of PAH deficiency.24 Large 
neutral amino acids (LNAAs) can also be used as the medical 
food for some individuals with PAH deficiency in conjunction 
with a more relaxed protein restriction.
Normal protein status, assessed by monitoring plasma amino 
acids and prealbumin, is achievable when total protein is 
Table 3 Recommended intakes of PHE, TYR, and protein for individuals with PAH deficiency
Age PHE (mg/day) TYR (mg/day) Proteina (g/kg)
Infant to <4 yearsb
  0 to <3 monthsc 130–430 1,100–1,300 3–3.5
  3 to <6 months 135–400 1,400–2,100 3–3.5
  6 to <9 months 145–370 2500–3000 2.5–3






  1 to <4 yearsd 200–320 2,800–3,500 ≥30
After early childhoode
  >4 years to adult 200–1,100 4,000–6,000 120–140% RDA for agef
Pregnancy/lactationg
  Trimester 1 265–770 6,000–7,600 ≥70
  Trimester 2 400–1,650 6,000–7,600 ≥70
  Trimester 3 700–2,275 6,000–7,600 ≥70
  Lactationh 700–2,275 6,000–7,600 ≥70
DRI, dietary reference intake; PAH, phenylalanine hydroxylase; PHE, phenylalanine; RDA, recommended dietary allowance;TYR, tyrosine.
aProtein recommendations for individuals consuming PHE-free amino acid–based medical foods as part of their protein source.
bRecommended intakes for infants and children <4 years of age are adapted from ref. 20 and are for individuals with a severe form of PAH deficiency treated with a PHE-
restricted diet alone.
cPHE requirements for premature infants with PAH deficiency may be higher.
dPHE tolerance is usually stable by 2–5 years of age as PHE requirements are based on a combination of size (increasing with age) and rate of growth (decreasing with age). 
For any individual, PHE intake is adjusted based on frequent blood PHE monitoring.
eAdapted from ref. 12. Range of PHE intake is for entire spectrum of PAH deficiency (mild to severe).
fRecommended protein intake greater than the RDA is necessary to support normal growth in PAH deficiency.
gRecommendations are slightly higher for pregnant women ≤19 years of age.
hDRI recommends that, for all women, nutrient intake during lactation be the same as during the third trimester of pregnancy.
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provided in appropriate amounts.18,21 Prealbumin is an accept-
able measure of protein status in individuals with PAH defi-
ciency.25 Mild protein insufficiency, as indicated by a preal-
bumin concentration of <20 mg/dl, has been associated with 
decreased linear growth.26
TYR is conditionally essential in PAH deficiency and must 
be added to the diet to maintain blood concentrations in 
the normal range. By itself, TYR supplementation does not 
improve neurological outcomes.27 All medical foods for the 
treatment of PAH deficiency are supplemented with TYR;15 
therefore, individuals who do not adhere to their prescribed 
intake of medical food may have inadequate blood concentra-
tions of TYR. In addition, TYR has a low solubility and may 
settle out of prepared medical foods during storage.15 Most 
clinicians monitor blood TYR routinely in individuals with 
PAH deficiency,9 and low plasma TYR has been documented 
among individuals treated with diet.28 One cause could be a 
diurnal variation in blood TYR.29 Supplementation beyond 
that provided by medical food with TYR is indicated only if 
blood TYR concentrations are consistently below the nor-
mal range. Fewer than 20% of clinicians in the IEM survey 
(D.M. Frazier, S.C. van Calcar, et al., personal communica-
tion) routinely prescribe TYR supplementation.
Energy
Because energy expenditure varies from person to person, 
energy requirements must be individually assessed. Most evi-
dence suggests that energy requirements are not increased in 
PAH deficiency, and carbohydrate and fat intakes are within 
established recommendations.30,31
Essential fatty acids
With adequate fat intake, children with PAH deficiency are 
found to have normal essential fatty acid (EFA) status.32 Medical 
foods supplemented with sources of long-chain polyunsaturated 
fatty acids increase blood concentrations of EFA.33 When a fat-
free medical food is provided or the diet contains inadequate 
sources of linoleic and α-linolenic acid, EFA status should be 
monitored.5 Both the IEM survey (D.M. Frazier, S.C. van Calcar, 
et al., personal communication) and the Delphi survey5 suggest 
that supplementation with precursor EFA, or with preformed 
docosahexaenoic acid (DHA), may be necessary in these indi-
viduals. In infancy, including breast milk or standard formulas 
containing DHA and arachidonic acid, as well as medical foods 
that contain DHA/arachidonic acid, can help ensure adequacy.
Micronutrients
Most medical foods available in the United States are supple-
mented with vitamins and minerals to provide micronutrients 
in amounts that meet recommendations. When a medical food 
does not contain adequate amounts of micronutrients or an 
individual’s intake is inadequate, a vitamin and mineral sup-
plement should be included in the treatment plan. Additional 
biochemical monitoring (Table 2) is indicated when there is a 
question about inadequate or excessive intake.
Minerals, including copper, manganese, and zinc,34 as well 
as selenium,35 have been reported as being deficient in the diet 
for PAH deficiency. However, these minerals are now added to 
most medical foods. Iron deficiency (without anemia) has been 
reported among individuals with PAH deficiency, and routine 
evaluation of iron status is recommended.36,37
Vitamin B12, as well as B6, deficiency may occur if there 
is inadequate consumption of medical food or animal pro-
tein.38 Severe megaloblastic anemia has been reported in 
adolescents and adults with PAH deficiency who are off-
diet.39 Because B12 deficiency can cause neurological defi-
cits,40 including memory loss, such symptoms could be erro-
neously attributed to high blood PHE. Supplementation is 
indicated if B12 markers remain low.
40 In addition, higher 
than normal plasma B12 levels have been reported in some 
on-diet individuals with PAH deficiency.41 Both exces-
sive and inadequate intakes of the fat-soluble vitamins A 
and D are possible with inappropriate medical food intake. 
Monitoring for clinical signs with subsequent biochemical 
testing is warranted.
There may be concerns with bone density that are unique 
to PAH deficiency. Decreased bone mineral density and bone 
mineral content, indicated by dual-energy X-ray absorptiom-
etry, have been noted.42,43 Osteopenia, defined as bone mineral 
density one or more SDs from normal reference for age and 
sex, is also seen44 but cannot be attributed to vitamin D con-
centrations alone. Some reports indicate that bone density is 
associated with adherence to nutrition therapy,45 whereas oth-
ers note decreased density across groups, stratified by calcium 
and phosphorus intakes42 and/or as compared with controls 
without PAH deficiency.43 Aberrant findings in protein mark-
ers, correlating to bone resorption or absorption, have also 
been reported.46,47 Further research is warranted to look at the 
effects of PAH deficiency itself, PAH deficiency management, 
and nutrient intake on bone density.
Anthropometrics
With adequate nutrient intake, appropriate growth can be 
expected for individuals with PAH deficiency.18,19 Impaired lin-
ear growth has been noted in children with PAH deficiency who 
had low plasma prealbumin concentrations.26 There is conflict-
ing evidence as to whether or not the rates of overweight and 
obesity in children with PAH deficiency are similar to those of 
the general population.30,48
clinical indicators
Physical findings associated with poorly controlled PAH defi-
ciency include osteopenia45 and dermatological problems.49 
Asthma, recurrent headache, eczema, neurological signs, 
hyperactivity, and/or lethargy have all been reported in adults 
with PAH deficiency who discontinued dietary treatment.50 
Psychological symptoms include phobias and depression.51 The 
majority of physical signs and symptoms of PAH deficiency 
reported in the literature resolved when blood PHE concentra-
tions were reduced to the treatment range.
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NUTRITION STRATEGIES FOR MANAGEMENT OF 
INDIVIDUALS WITH PAH DEFIcIENcY
Selecting medical food
Medical foods provide necessary protein equivalents in the 
diets of individuals with PAH deficiency, and selecting the 
appropriate medical food can affect both dietary compliance 
and nutritional status. There are more than 30 medical foods 
available for the treatment of PAH deficiency, and they can 
be classified by the age for which they are intended and by 
macronutrient composition (Table 4). Infant medical foods 
typically lack only PHE. Products designed for children, 
adolescents, and adults vary widely in protein, fat, vitamin, 
and mineral content to meet individual taste and nutrient 
needs, but many are nutritionally incomplete. The macro- 
and micronutrient profiles of many medical foods for IEM 
are available at http://www.gmdi.org. Medical food should be 
consumed throughout the day and divided into at least three 
servings because more frequent consumption of medical 
foods is associated with better PHE tolerance13 and improved 
plasma PHE concentrations.8
Medical foods are available in a variety of flavors and in dif-
ferent forms (i.e., powders, ready-to-drink liquids, tablets, and 
bars). Convenience packaging and alternative forms of medical 
foods typically cost more than the powdered forms. Although 
insurance coverage of medical foods is mandated in some 
states, there are exceptions and limitations. Therefore, access 
to medical food is not guaranteed in the United States, and 
obtaining coverage can be an arduous process.52 This is due, in 
part, to the fact that medical foods are not prescription medi-
cations but have a unique classification by the Food and Drug 
Administration that was intended to promote the development 
of more products for PAH deficiency and other orphan dis-
eases.53 The classification allows a less costly regulatory process 
necessary to get medical foods to market.
Table 4 Classification of medical foodsa
classification









Nutrient profile Most complete Most vitamins and 
minerals, no fat
Few or no vitamins 
and minerals and 
no fat
Variable depending 







High to medium Medium to low Low Variable Low








Periflex Infante, Phenex-1f, 
Phenyl-Free1g




2f, PhenylAde Essentiale, 
Phenyl-Free 2g
Lophlexe,PhenylAde 40e, 
PKU Coolersh,PKU Gelh, 
Maxamaid XPe
None BetterMilk <12i, None
Complete bars <12i, 
Restorei
Products designed 
for adolescents and 
adultsd
Periflex Advance,  
Phenex-2f, PhenylAde 





PhenylAde 60e, PKU 
Coolersh, Maxamum XPe
PhenylAde Amino 
Acid Blende and 









aExamples of products available in the United States as of May 2013. Inclusion in table does not represent endorsement.
bEnergy/protein ratio categories (kcal/g): low, 4–9; medium, 10–19; high, >20.
cSome products are not appropriate for children <4 years; check manufacturer’s information for nutrient profile.
dSome products may be used before adolescence, especially if used in combination with other products, depending on clinical circumstances.
eNutricia North America, Gaithersburg, MD.
fAbbott Nutrition, Columbus, OH.
gMead Johnson Nutrition, Evansville, IN.
hVitaflo USA, Alexandria, VA.
iCambrooke Foods, Ayer, MA.
REcOMMENDATIONS
•	 Provide the same nutrient intakes as those of the general 
population, except for PHE, TYR, and protein.
•	 Assess the need for vitamin/mineral supplementation 
when a medical food without complete vitamins and min-
erals is used or when there is insufficient adherence with 
medical food intake.
•	 Monitor nutrition status by assessing anthropometrics, 
clinical signs and symptoms, nutrient intake, and labora-
tory indexes of metabolic control and nutrition adequacy 
(Table 2).
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Glycomacropeptide
GMP is an intact whey protein low in PHE, TYR, histidine, 
leucine, tryptophan, and arginine. All except PHE must be 
added as free l-amino acids to provide an appropriate pro-
tein source for PAH deficiency.54 Although long-term efficacy 
and growth studies are lacking, a short-term inpatient study 
found no safety concerns when GMP products replaced 
amino acid–based medical food.54 Various markers pointed 
to improved protein utilization,54 and lower ghrelin concen-
trations suggested improved satiety when GMP products 
replaced each subject’s usual amino acid–based medical food 
as the protein source.55 Medical food products incorporating 
GMP are an alternative to PHE-free amino acid formulas. 
Because GMP contains a small amount of PHE (2–5 mg PHE 
per gram of protein),54 the allowance of PHE from food may 
need to be reduced to maintain PHE intake within PHE toler-
ance limits.23
Large neutral amino acids
The theory behind LNAA use as a medical food is described 
in the ACMG guideline.4 LNAAs are not recommended for 
young children or pregnant women but should be considered 
for adults with PAH deficiency who are not in good metabolic 
control and do not adhere to other treatment options.5 LNAA 
therapy has been shown to improve executive function in some 
adults.56 When using LNAAs, 25–30% of total protein needs 
are provided by LNAAs, with the remaining 70–75% com-
ing from dietary protein sources.57 Protein intake and plasma 
amino acids should be monitored to prevent essential amino 
acid deficiencies. It is difficult to monitor the success of LNAA 
therapy because blood PHE remains high, and measurement of 
PHE concentration in the brain is impractical. Blood and urine 
melatonin have been suggested as surrogate markers for sero-
tonin and may be useful in monitoring treatment.58 Serotonin 
has been shown to be deficient in individuals with PAH defi-
ciency who exhibit executive function defects.58
Providing dietary PHE
Because PHE is an essential amino acid, limited amounts from 
intact protein must be provided for anabolic processes regard-
less of the medical food chosen. For infants, the source of PHE 
can be either breast milk59 or infant formula (containing DHA/
arachidonic acid). A variety of strategies for introducing breast 
milk have been described.59 Although there is little consensus 
about the best way to incorporate breast milk into the diet of 
an infant with PAH deficiency, there is agreement that feeding 
at the breast, as well as feeding expressed breast milk by bottle, 
results in good metabolic control.60 Later in the first year, breast 
milk or infant formula is slowly removed in exchange for lim-
ited amounts of intact protein from solid foods containing an 
equivalent amount of PHE.
Tracking dietary PHE
There is little consensus about the best method for tracking 
dietary PHE intake. As long as data are available on the PHE 
content of individual food items, the most precise method 
of tracking PHE intake is counting milligrams of PHE. An 
exchange system (1 exchange = 15 mg PHE) is easier for 
some patients and families. Those with higher PHE toler-
ance may be able to achieve good PHE control by counting 
grams of protein. This has the advantage of allowing the use 
of food labels as a guide. A more liberal approach of allowing 
“free” consumption of fruits, vegetables, and low-PHE foods 
(<100 mg PHE/100 g) allows for similar blood PHE control to 
that of other tracking methods.61 This system has been used 
by clinics in Europe with good success but is not common 
practice in the United States.5
Modified low-protein foods
Individuals with severe forms of PAH deficiency and low PHE 
tolerance often rely on modified low-protein foods to provide 
energy and variety in their diets.15 Modified low-protein foods, 
including low-protein breads and pasta, use the starch portion 
of the grain rather than the higher-protein flour.62 It is impor-
tant to note that these products do not have the usual vitamin 
enrichment found in regular grain products. As a source of 
energy, these products can help to prevent weight loss, catabo-
lism, and the resulting elevated blood PHE.15 Third-party reim-
bursement for modified low-protein foods is not universally 
available.52
Sapropterin (tetrahydrobiopterin) therapy
Sapropterin dihydrochloride (sapropterin) is the pharmaceuti-
cal form of tetrahydrobiopterin, a cofactor required for PAH 
activity. Given in therapeutic doses, sapropterin appears to 
enhance PAH activity in certain individuals with PAH defi-
ciency.63 The ACMG PAH deficiency guideline recommends a 
trial of sapropterin therapy for all individuals.4 The benefits of 
response fall into two categories: for individuals who are non-
adherent or unable to maintain diet restriction and medical 
food intake, sapropterin may lower blood PHE without further 
diet modification; and for individuals who maintain blood PHE 
within the therapeutic range by dietary adherence, sapropterin 
may allow liberalization of dietary PHE and less medical food 
intake.64
Although sapropterin therapy may support significant dietary 
liberalization, it seldom allows individuals to maintain appro-
priate blood PHE without some PHE restriction and medical 
food. Regular monitoring of blood PHE, dietary adequacy, 
and nutritional status continue to be essential. Individualized 
patient counseling includes planning and calculating the diet 
with a higher PHE or protein allowance, choosing appropriate 
natural protein sources, reading labels, distributing high-PHE/
intact protein foods throughout the day, meeting micronutri-
ent/vitamin requirements when the medical food prescription 
is decreased, and understanding the importance of consistent 
sapropterin dosing.65,66 Longer-term follow-up will be neces-
sary to determine whether individuals with PAH deficiency 
remain adherent to sapropterin and dietary recommendations 
and if there is an impact on outcome.
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Nutrition counseling and education
Nutrition counseling and education involve teaching individuals 
with PAH deficiency and/or their caregivers the importance of 
the diet in maintaining appropriate blood PHE, normal growth, 
and health maintenance while ensuring that they have the 
necessary skills to adhere to the diet throughout the life span. 
Education techniques and materials must be appropriate for the 
individual’s learning style,67 access to care, acceptance of the diet, 
and/or readiness for change. Research into effective education 
and counseling strategies for PAH deficiency is lacking.
TREATMENT IN SPEcIAL cIRcUMSTANcES
Pregnancy in women with PAH deficiency
High maternal blood PHE is associated with poor outcomes in 
offspring, including low birth weight, microcephaly, congenital 
heart defects, and intellectual disability. Maintaining maternal 
blood PHE between 120 and 360 μmol/l before and during 
pregnancy results in the best outcome for offspring.2 However, 
30% of clinics surveyed recommend 120–240 μmol/l as the tar-
get range for maternal blood PHE.5
Most studies have not evaluated the effect of nutrition 
(beyond maternal blood PHE) on outcomes. In the Maternal 
PKU Collaborative Study, maternal protein intake and energy 
were significantly and negatively correlated with blood PHE 
throughout the entire pregnancy.68 Women with low protein 
intake secondary to inadequate consumption of medical food 
also had low overall nutrient intake and a higher incidence of 
congenital anomalies in their offspring.69 Adequate energy and 
fat intake, as well as adequate weight gain, have all been associ-
ated with better pregnancy outcomes.68 Control of nausea and 
vomiting, especially in early pregnancy, is key to preventing 
catabolic weight loss and elevated PHE levels. Neither TYR 
intake nor blood TYR has been reported to be associated with 
outcomes in maternal PAH deficiency.70 Fat and essential fatty 
acid intakes may be very low in individuals with PAH deficiency 
when their medical food contains no fat. DHA supplementa-
tion of 200–300 mg/day should be provided to all pregnant 
women with PAH deficiency.5 Specific monitoring recommen-
dations during pregnancy for women with PAH deficiency are 
outlined in Table 2. The use of adjunctive therapies in manag-
ing blood PHE during pregnancy is a matter of debate. LNAA 
monotherapy is not recommended, because it does not result in 
adequate control of blood PHE. Because sapropterin can lower 
blood PHE, its use should be considered on a case-by-case 
basis.5 Women are encouraged to continue the diet in the post-
partum period and can breast-feed their non–PAH-deficient 
infant regardless of maternal blood PHE levels.
Sick days and catabolism
Infection, inflammation, and injury induce a catabolic state, 
with increased endogenous protein breakdown and impaired 
anabolism. For individuals with PAH deficiency, this can lead 
to increased blood PHE; however, there are no published data, 
nor is there consensus regarding “sick day” management. 
Specialized parenteral nutrition solutions have been used when 
adequate enteral intake is not possible.71
Late-treated PAH deficiency
Improvements in behavior and functioning have been docu-
mented in previously untreated individuals with PAH deficiency 
who have been placed on diet therapy.72,73 In children for whom 
therapy was delayed, improvement in IQ may occur after nutri-
tion therapy is initiated.72,73 Choice of treatment modality should 
be based on feasibility and effectiveness for the individual 
patient. Among the concerns are comorbidities, contraindica-
tions due to prescribed medications, and limited access to care.
PSYcHOSOcIAL SUPPORT
Treatment for PAH deficiency is complex, and adherence to rec-
ommendations diminishes with age.74 The companion ACMG 
PAH deficiency treatment guideline4 discusses the problems 
and challenges faced by individuals with PAH deficiency as they 
transition into adulthood.4 Adherence improves if individuals 
have a social support system; an understanding of the benefits 
of treatment; access to appropriate care, medical foods and 
REcOMMENDATIONS
•	 Evaluate individual nutritional needs, ability to adhere to 
recommendations, and access to treatment options when 
choosing appropriate interventions (medical food, modi-
fied low-protein food, sapropterin, and LNAAs) to achieve 
blood PHE in the target range.
•	 Provide counseling and education specific to the needs of 
the individual with PAH deficiency (and/or his/her caregiv-
ers) to help maintain appropriate blood PHE throughout 
the life span.
•	 Recommend that medical food be consumed throughout 
the day for optimal metabolic control.
•	 Include breast milk and/or infant formula as sources of 
PHE in the diet of an infant with PAH deficiency.
•	 Track PHE intake by any of several methods, including 
counting milligrams or exchanges of PHE or grams of pro-
tein.
•	 Consider use of LNAAs in adults with PAH deficiency who 
are not in good metabolic control and not able to adhere 
to other treatment options.
•	 Individualize the diets of responders to sapropterin with 
appropriate PHE, medical foods, or modified low-protein 
food intake and/or vitamin/mineral supplementation to 
ensure adequate nutrient intake.
REcOMMENDATIONS
•	 Maintain blood PHE between 120 and 360 μmol/l before 
conception and throughout pregnancy.
•	 Monitor dietary intake of pregnant women with PAH de-
ficiency to ensure nutrient adequacy.
•	 Consider sapropterin use on a case-by-case basis for preg-
nant women who have difficulty adhering to the diet.
•	 Do not recommend LNAAs for use in pregnant women 
with PAH deficiency.
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modified low-protein foods; and a belief that PAH deficiency is 
manageable.75 Special support and advocacy are frequently nec-
essary to secure access to the medical foods required by individ-
uals with PAH deficiency.2,51 Creative approaches for clinic- and 
community-based programs, such as age-specific educational 
programs, camps, and other support programs, hold promise 
for improving adherence and quality of life.
cONcLUSION
Nutrition management of PAH deficiency has resulted in 
remarkable outcomes for individuals who have benefitted from 
early diagnosis and treatment. These positive outcomes are the 
sum of dedicated research, clinical attentiveness, and patient 
adherence. Although much has been learned about providing 
proper nutrition on a PHE-restricted diet, many aspects of diet 
and health in individuals with PAH deficiency require further 
investigation. These include issues such as adequacy of absorp-
tion of nutrients from medical foods, bone density, weight sta-
tus, long-term neurocognitive outcomes, and oxidative stress, 
as well as the roles of less available nutrients (e.g., menaquinone 
and vitamin K2) and functional nonnutrients (e.g., nucleo-
sides, nucleotides, pre- and probiotics, and polyphenolic com-
pounds). How to balance nutrition management with other 
treatments, such as LNAAs, sapropterin, and PEGylated phe-
nylalanine lyase, and the impact of genotype on treatment are 
still being explored. Continued research should also examine 
approaches that promote adherence to therapy. The health-care 
system must ensure that individuals with PAH deficiency have 
access to the care necessary for optimal outcomes.
These recommendations for the nutrition management of 
individuals with PAH deficiency reflect the latest in scientific 
understanding and clinical practice. The workgroup is con-
tinuing, with evidence and consensus methodology, to develop 
comprehensive nutritional management guidelines, resources, 
and tools for PAH deficiency that will be made available on the 
Genetic Metabolic Dietitians International and the Southeast 
Regional Genetics Collaborative websites.
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